COVID-19 Human Challenge Study: COVHIC002

Recruiting Now!
We are looking for healthy volunteers aged 18 – 30 years old to take part in a new COVID-19 Human Challenge Study.
We are looking for healthy volunteers aged 18 – 30 years old to take part in a new COVID-19 Human Challenge Study.
In this study, we are trying to find out how we can best protect people against pertussis (more commonly known as whooping cough). Pertussis is a highly contagious infection of the lungs and airways, caused by bacteria (small organisms which can reproduce and cause illness) called Bordetella pertussis (B. pertussis). The groups of people most severely affected by pertussis are babies, the elderly, people with chronic medical conditions that affect the lungs and heart, and people who are immunocompromised (unable to respond normally to an infection).
You are invited to take part in a study to investigate whether a novel vaccine can prevent paratyphoid fever. The study is being run by the Oxford Vaccine Group which is part of the University of Oxford, in collaboration with multiple NHS Trusts across the UK, and is funded by the Medical Research Council.
MenABCWY=Men7B-003 : A Phase II, randomised, partially blinded study to assess the safety, tolerability, and immunogenicity of meningococcal combined ABCWY vaccine when administered to healthy infants.
Short Title: Combining vaccines against meningitis: An infant immunisation study
Oxford Vaccine Group would like to invite your baby to participate in a study looking at a new combined Meningitis vaccine, designed to allow us to give babies protection against many different strains of meningitis using fewer injections.
What is the purpose of this study and why participate?
SARS-CoV-2 is the virus responsible for COVID-19 disease. Recent roll out of licensed vaccines is a positive step towards fighting COVID-19. However, we don’t know how long protection after COVID-19 infection and/ or vaccination lasts and why some people can get infected a second time..
The Oxford Vaccine Group is recruiting infants aged 4 – 7 months to a type 1 diabetes prevention trial. POInT (Primary Oral Insulin Trial) is recruiting infants who were screened for diabetes at birth through the INGR1D Study and have been found to be at high risk for developing diabetes.
Are you a parent or guardian of a child aged 0-5 years?
You may be interested in taking part in a study about vaccine attitudes.
This study is run by Oxford Vaccine Group, part of the University of Oxford.
What is the study about?
We will be holding focus groups (discussions) with small groups of parents of children aged 0-5 years.